The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus

Therapeutic Delivery

Volumn 8, Issue 6, 2017, Pages 401-409

  Woodhams, Louise ^a   Al Salami, Hani ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

bile acids; diabetes mellitus; inflammation; microencapsulation; cells

Indexed keywords

BILE ACID; GLUCOSE;

ABSORPTION; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; DIABETIC PATIENT; ENERGY BALANCE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MICROENCAPSULATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GLUCOSE BLOOD LEVEL;

BILE ACIDS AND SALTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 85019921810     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde-2017-0010     Document Type: Review

References (86)

1. Mooranian A, Negrulj R, Mathavan S et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm. Dev. Technol. 20(6), 702-709 (2015).
2. Barnett R. Historical keyword: diabetes. Lancet 375(9710), 191 (2010).
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with Type 2 diabetes. Diabetes 52(1), 102-110 (2003).
4. Negrulj R, Mooranian A, Al-Salami H. Potentials and limitations of bile acids in type 2 diabetes mellitus: applications of microencapsulation as a novel oral delivery system. J. Endocrinol. Diabetes Mellit. 1(2), 49-59 (2013).
5. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in Type 1 diabetes: 'Double diabetes' in the diabetes control and complications trial. Diabetes Care 30(3), 707-712 (2007).
6. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104(3), 979-984 (2007).
7. Duboc H, Rajca S, Rainteau D et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62(4), 531-539 (2013).
8. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol. 75(3), 207-246 (2005).
9. Peng S, Zhao S, Yan F et al. HDAC2 selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. J. Neurosci. 35(3), 1250-1259 (2015).
10. Booth DM, Murphy JA, Mukherjee R et al. Reactive oxygen species induced by bile acid induce apoptosis and protect against necrosis in pancreatic acinar cells. Gastroenterology 140(7), 2116-2125 (2011).
11. Houten S, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 25(7), 1419-1425 (2006).
12. Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol. Sci. 14(1), 24-29 (1999).
13. Perdigon G, Maldonado Galdeano C, Valdez JC, Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur. J. Clin. Nutr. 56(Suppl. 4), S21-S26 (2002).
14. Wu HJ, Ivanov II, Darce J et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32(6), 815-827 (2010).
15. De Leon M, Ferenderes R, Carulli N. Bile lipid composition and bile acid pool size in diabetes. Am. J. Dig. Dis. 23(8), 710-716 (1978).
16. Hassan AS, Subbiah MT. Effect of diabetes during pregnancy on maternal and neonatal bile acid metabolism in the rat. Proc. Soc. Exp. Biol. Med. 165(3), 490-495 (1980).
17. Thomson AB. Unidirectional flux rate of cholesterol and fatty acids into the intestine of rats with drug-induced diabetes mellitus: effect of variations in the effective resistance of the unstirred water layer and the bile acid micelle. J. Lipid Res. 21(6), 687-698 (1980).
18. Sharma R, Majer F, Peta VK et al. Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A). Bioorg. Med. Chem. 18(18), 6886-6895 (2010).
19. Dent P, Han SI, Mitchell C et al. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochem. Pharmacol. 70(11), 1685-1696 (2005).
20. Stepanov V, Stankov K, Mikov M. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J. Recept. Signal. Transduct. Res. 33(4), 213-223 (2013).
21. Whelehan M, Marison IW. Microencapsulation using vibrating technology. J. Microencapsul. 28(8), 669-688 (2011).
22. Ehses JA, Donath MY. Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes. Diabetologia 58(3), 425-428 (2015).
23. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 88(3), 1082-1088 (2003).
24. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in Type 1 diabetes. Nat. Rev. Endocrinol. 5(4), 219-226 (2009).
25. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with Type 1 diabetes. Diabetes 55(3), 774-779 (2006).
26. Higai K, Azuma Y, Aoki Y, Matsumoto K. Altered glycosylation of alpha1-acid glycoprotein in patients with inflammation and diabetes mellitus. Clin. Chim. Acta 329(1-2), 117-125 (2003).
27. Kullmann F, Gross V, Ruschoff J et al. Effect of ursodeoxycholic acid on the inflammatory activity of indomethacin-induced intestinal inflammation in rats. Z. Gastroenterol. 35(3), 171-178 (1997).
28. Martinez-Moya P, Romero-Calvo I, Requena P et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int. Immunopharmacol. 15(2), 372-380 (2013).
29. Mooranian A, Negrulj R, Arfuso F, Al-Salami H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Deliv. Transl. Res. 5(5), 511-522 (2015).
30. Van Nierop FS, Kulik W, Endert E et al. Effects of acute dietary weight loss on postprandial plasma bile acid responses in obese insulin resistant subjects. Clin. Nutr. doi:10.1016/j. clnu.2016.10.006 (2016) (Epub ahead of print).
31. Mikov M, Fawcett JP. Chemistry, biosynthesis, analysis, chemical & metabolic transformations and pharmacology. Eur. J. Drug. Metab. Pharmacokinet. 31(3), 133-134 (2006).
32. Mikov M, Fawcett JP, Kuhajda K, Kevresan S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents. Eur. J. Drug. Metab. Pharmacokinet. 31(3), 237-251 (2006).
33. Mikov M, Raskovic A, Kuhajda K, Kevresan S, Potsides CY. Therapeutic perspective of bile acids-toxicity and interaction. Scr. Med. 1(Suppl. 1), S1 (2004).
34. Meinders AE, Van Berge Henegouwen GP, Willekens FL, Schwerzel AL, Ruben A, Huybregts AW. Biliary lipid and bile acid composition in insulin-dependent diabetes mellitus. Arguments for increased intestinal bacterial bile acid degradation. Dig. Dis. Sci. 26(5), 402-408 (1981).
35. Mikov M, Boni NS, Al-Salami H, Kuhajda K, Kevresan S, Fawcett JP. Pharmacokinetics and hypoglycaemic effect of 3 alpha, 7 alpha-dihydroxy-12-oxo-5beta-cholanate (MKC) in diabetic rat. FEBS J. 273, 210 (2006).
36. Al-Salami H, Kansara H, King J et al. Bile acids: a bitter sweet remedy for diabetes. New Zealand Pharm. J. 27(10), 17-20 (2007).
37. Mikov M, Boni NS, Al-Salami H et al. Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha, 7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur. J. Drug Metab. Pharmacokinet. 32(1), 7-12 (2007).
38. Al-Salami H, Butt G, Tucker I, Mikov M. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find. Exp. Clin. Pharmacol. 30(2), 107-113 (2008).
39. Calasan J, Al-Salami H, Mikov M. Bile acids and probiotics could help treating diabetes. FEBS J. 279, 267-268 (2012).
40. Chong ZZ, Hou J, Shang YC, Wang S, Maiese K. EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3beta, and beta-catenin to foster vascular integrity during experimental diabetes. Curr. Neurovasc. Res. 8(2), 103-120 (2011).
41. Fu D, Wu M, Zhang J et al. Mechanisms of modified LDL-induced pericyte loss and retinal injury in diabetic retinopathy. Diabetologia 55(11), 3128-3140 (2012).
42. Li T, Chiang JY. Bile acid signaling in liver metabolism and diseases. J. Lipids 754067 doi:10.1155/2012/754067 ( (2012) () (Epub ahead of print).).
43. Prawitt J, Caron S, Staels B. Bile acid metabolism and the pathogenesis of Type 2 diabetes. Curr. Diab. Rep. 11(3), 160-166 (2011).
44. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89(1), 147-191 (2009).
45. Monte MJ, Marin JJ, Antelo A, Vazquez-Tato J. Bile acids: chemistry, physiology, and pathophysiology. World J. Gastroenterol. 15(7), 804-816 (2009).
46. Lorbek G, Lewinska M, Rozman D. Cytochrome P450s in the synthesis of cholesterol and bile acids - from mouse models to human diseases. FEBS J. 279(9), 1516-1533 (2012).
47. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig. Dis. 29(1), 37-44 (2011).
48. Makino I, Shinozaki K, Yoshino K, Nakagawa S. Dissolution of cholesterol gallstones by long-term administration of ursodeoxycholic acid. Nihon Shokakibyo Gakkai Zasshi 72(6), 690-702 (1975).
49. Bennion LJ, Grundy SM. Effects of diabetes mellitus on cholesterol metabolism in man. N. Engl. J. Med. 296(24), 1365-1371 (1977).
50. Abrams JJ, Ginsberg H, Grundy SM. Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31(10), 903-910 (1982).
51. Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochim. Biophys. Acta 1802(3), 363-372 (2010).
52. Small DM, Dowling RH, Redinger RN. The enterohepatic circulation of bile salts. Arch. Intern. Med. 130(4), 552-573 (1972).
53. Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology 48(5), 1383-1386 (2008).
54. Thistle JL, Larusso NF, Hofmann AF, Turcotte J, Carlson GL, Ott BJ. Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study. Dig. Dis. Sci. 27(2), 161-168 (1982).
55. Hassan AS, Subbiah MT, Thiebert P. Specific changes of bile acid metabolism in spontaneously diabetic Wistar rats. Proc. Soc. Exp. Biol. Med. 164(4), 449-452 (1980).
56. Hassan AS, Hedeen K, Subbiah MT. Effect of maternal diabetes on fetal bile acid metabolism in the rat. Biochem. Med. 25(2), 168-173 (1981).
57. Nervi FO, Gonzalez A, Valdivieso VD. Studies on cholesterol metabolism in the diabetic rat. Metabolism 23(6), 495-503 (1974).
58. Wey HE, Yunker RL, Harris P, Subbiah MT. Effect of streptozotocin-induced diabetes in neonatal rat on bile acid pool changes in adult life: selective sensitivity in females. Biochem. Med. 31(2), 167-173 (1984).
59. van Waarde WM, Verkade HJ, Wolters H et al. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology 122(7), 1842-1852 (2002).
60. Kobayashi M, Ikegami H, Fujisawa T et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56(1), 239-247 (2007).
61. Staels B, Kuipers F. Bile acid sequestrants and the treatment of Type 2 diabetes mellitus. Drugs 67(10), 1383-1392 (2007).
62. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 25(7), 1419-1425 (2006).
63. Roesch LF, Lorca GL, Casella G et al. Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J. 3(5), 536-548 (2009).
64. Meadows R. Gut bacteria may override genetic protections against diabetes. PLoS Biol. 9(12), e1001215 (2011).
65. Siow Y, Schurr A, Vitale GC. Diabetes-induced bile acid composition changes in rat bile determined by high performance liquid chromatography. Life Sci. 49(18), 1301-1308 (1991).
66. Nervi FO, Severin CH, Valdivieso VD. Bile acid pool changes and regulation of cholate synthesis in experimental diabetes. Biochim. Biophys. Acta 529(2), 212-223 (1978).
67. Chen L, Yao X, Young A et al. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am. J. Physiol. Endocrinol. Metab. 302(1), E68-E76 (2012).
68. Vasovic V, Vukmirovic S, Posa M, Mikov M, Raskovic A, Jakovljevic V. Effect of rat pretreatment with aqueous solutions of stevioside and bile acids on the action of certain cardioactive drugs. Eur. J. Drug Metab. Pharmacokinet. 31(4), 311-314 (2006).
69. Thomson AB. Uptake of bile acids into rat intestine. Effect of diabetes mellitus. Diabetes 32(10), 900-907 (1983).
70. Lukivskaya O, Patsenker E, Buko VU. Protective effect of ursodeoxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci. 80(26), 2397-2402 (2007).
71. Wu T, Bound MJ, Standfield SD, Jones KL, Horowitz M, Rayner CK. Effects of taurocholic acid on glycemic, glucagon-like peptide-1, and insulin responses to small intestinal glucose infusion in healthy humans. J. Clin. Endocrinol. Metab. 98(4), E718-E722 (2013).
72. Kars M, Yang L, Gregor MF et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 59(8), 1899-1905 (2010).
73. Schaumberg DA, Glynn RJ, Jenkins AJ et al. Effect of intensive glycemic control on levels of markers of inflammation in Type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 111(19), 2446-2453 (2005).
74. Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat. Rev. Immunol. 3(7), 534-543 (2003).
75. Luzina IG, Keegan AD, Heller NM, Rook GA, Shea-Donohue T, Atamas SP. Regulation of inflammation by interleukin-4: a review of 7quot;alternatives7quot;. J. Leukoc. Biol. 92(4), 753-764 (2012).
76. Shahidi F, Han XQ. Encapsulation of food ingredients. Crit. Rev. Food. Sci. Nutr. 33(6), 501-547 (1993).
77. Chang PL, Van Raamsdonk JM, Hortelano G, Barsoum SC, Macdonald NC, Stockley TL. The in vivo delivery of heterologous proteins by microencapsulated recombinant cells. Trends Biotechnol. 17(2), 78-83 (1999).
78. Sliwka W. Microencapsulation. Angew. Chem. Int. Ed. Engl. 14(8), 539-550 (1975).
79. Murua A, Portero A, Orive G, Hernandez RM, De Castro M, Pedraz JL. Cell microencapsulation technology: towards clinical application. J. Control Rel. 132(2), 76-83 (2008).
80. Orive G, Hernandez RM, Rodriguez Gascon A et al. History, challenges and perspectives of cell microencapsulation. Trends Biotechnol. 22(2), 87-92 (2004).
81. Mooranian A, Negrulj R, Chen-Tan N et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, probucol. Drug Des. Devel. Ther. 8, 1221-1230 (2014).
82. Chung TW, Yang J, Akaike T et al. Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment. Biomaterials 23(14), 2827-2834 (2002).
83. Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials 24(24), 4337-4351 (2003).
84. George M, Abraham TE. Polyionic hydrocolloids for the intestinal delivery of protein drugs: alginate and chitosan - a review. J. Control. Release 114(1), 1-14 (2006).
85. Mooranian A, Negrulj R, Chen-Tan N, Watts GF, Arfuso F, Al-Salami H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des. Devel. Ther. 8, 1673-1683 (2014).
86. Mooranian A, Negrulj R, Chen-Tan N et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des. Devel. Ther. 8, 1003-1012 (2014).